FDA Clinical Investigator Training Course (CITC) 2023, Day 1 - Part 1

Поделиться
HTML-код
  • Опубликовано: 3 янв 2024
  • This course was designed to promote professionalism in the clinical trial industry for individuals involved with submissions to FDA (Investigational New Drug (IND) application, New Drug Application (NDA), Biologics License Application (BLA)), and to familiarize stakeholders with the regulatory and scientific issues involved in the development and approval of medical drugs and biological products.
    Timestamps
    00:01 - Day One Welcome
    00:36 - FDA Structure and Mandate
    20:25 - Basics of Clinical Trial Design - Design, Population, Intervention, Outcomes
    52:02 - Digital Health Technologies & Decentralized Clinical Trials
    01:22:19 - Real-World Evidence (RWE)
    01:39:00 - Q&A Discussion Panel
    Speakers | Panelists:
    Leonard Sacks, MBBCh
    Associate Director for Clinical Methodologies
    Offie of Medical Policy (OMP)
    CDER | FDA
    Kimberly Smith, MD, MS
    CAPT | USPHS
    Real World Evidence Analytics
    OMP | CDER | FDA
    Fortunato Fred Senatore, MD, PhD, FACC
    Lead Physician
    Division of Cardiology and Nephrology (DCN)
    Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN)
    Office of New Drugs (OND)
    CDER | FDA
    John Concato, MD
    Associate Director of Real-World Evidence
    OMP | CDER | FDA
    Learn more at: www.fda.gov/drugs/news-events...
    -----------------------
    FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
    Upcoming Training - www.fda.gov/cdersbia
    SBIA Listserv - public.govdelivery.com/accoun...
    SBIA 2022 Playlist - • 2022 CDER Small Busine...
    SBIA LinkedIn -  / cder-small-business-an...
    SBIA Training Resources - www.fda.gov/cdersbialearn
    Twitter -  / fda_drug_info
    Email - CDERSBIA@fda.hhs.gov
    Phone - (301) 796-6707 I (866) 405-5367
  • НаукаНаука

Комментарии •